Initial screens have pinpointed checkpoint kinase inhibition as an effective combination with gemcitabine treatment in pancreatic cancer cells [2], MEK inhibition as an effective combination with EGFR inhibition in KRAS wild-type cells pancreatic cancer cells [3], and inhibition of Wnt/Ca2+/NFAT signaling as an enhancer of BCR-ABL inhibition in CML cells [4]. Here, KRAS is linked to pancreatic neoplasm.